 Home > Active Ingredient News > Antitumor Therapy > JCO: Prostate cancer patients with high risk of recurrence/death may be consolidated with adjuvant radiotherapy after radical resection

JCO: Prostate cancer patients with high risk of recurrence/death may be consolidated with adjuvant radiotherapy after radical resection

 Last Update: 2021-06-16
 Source: Internet
 Author: User

Tags

flomax prostate

leave hair treatment

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

In randomized controlled trials, adjuvant radiotherapy did not show the potential to reduce progression-free survival compared with early rescue radiotherapy (sRT) after radical prostatectomy (RP)

In this study, Derya et al.

Adjusted risk assessment of all-cause death: A) 2424 patients with pathological dysfunction in pN1 stage; B) 933 patients with pathological dysfunction in pN1 stage; C) 23694 patients with pathological dysfunction

After a median follow-up of 8.

Prostate cancer patients with pN1 stage or pGleason score 8-10 points and pT3/4 stage may consider adjuvant radiotherapy, which is expected to significantly reduce their risk of all-cause death pN1 stage or pGleason score 8-10 points and pT3/4 stage Prostate cancer patients may consider adjuvant radiotherapy, which is expected to significantly reduce the risk of all-cause death

Original source:

Derya Tilki, et al.

Leave a message here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Gefitinib

CAS No.: 184475-35-2

Pharmacy Grade

$1/MT FOB

High quality Sunitinib CAS NO 557795-19-4 Orange solid powder 99% API for antitumor

CAS No.: 557795-19-4

Pharmacy Grade

$4.1-4.2/G FOB

Epirubicin

CAS No.: 56420-45-2

$1/KG EXW

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

announcements today(81)

80 20 company(94)

united states logo(227)

single use technology(195)

healthy food name(42)

ups united states(221)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.